Incannex Healthcare Inc.
NCM: IXHLLive Quote
📈 ZcoreAI Score
Our AI model analyzes Incannex Healthcare Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get IXHL Z-Score →About Incannex Healthcare Inc.
Healthcare
Drug Manufacturers - Specialty & Generic
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
📊 Fundamental Analysis
Incannex Healthcare Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -130.4%, which indicates that capital utilization is currently under pressure.
At a current price of $3.12, IXHL currently trades near the bottom of its 52-week range (2%), indicating potential value or weakness (Range: $2.40 - $49.80).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$43.60M
Trailing P/E
--
Forward P/E
-1.59
Beta (5Y)
2.73
52W High
$49.80
52W Low
$2.40
Avg Volume
494K
Day High
Day Low